Načítá se...
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
The objective of this study was to report our experience with weekly low-dose docetaxel (DOC) chemotherapy for patients with castration-resistant prostate cancer (CRPC). From 2007 to 2014, 39 consecutive patients received weekly low-dose DOC; the oncological effectiveness, side effects and tolerabil...
Uloženo v:
| Vydáno v: | Mol Clin Oncol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4887800/ https://ncbi.nlm.nih.gov/pubmed/27284427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.830 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|